EP2970218B8 - Inhibiteurs d'adn-pk - Google Patents
Inhibiteurs d'adn-pk Download PDFInfo
- Publication number
- EP2970218B8 EP2970218B8 EP14719434.4A EP14719434A EP2970218B8 EP 2970218 B8 EP2970218 B8 EP 2970218B8 EP 14719434 A EP14719434 A EP 14719434A EP 2970218 B8 EP2970218 B8 EP 2970218B8
- Authority
- EP
- European Patent Office
- Prior art keywords
- inhibitors
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL14719434T PL2970218T3 (pl) | 2013-03-12 | 2014-03-12 | Inhibitory DNA-PK |
RS20190243A RS58374B1 (sr) | 2013-03-12 | 2014-03-12 | Inhibitori dnk-pk |
MEP-2019-55A ME03336B (fr) | 2013-03-12 | 2014-03-12 | Inhibiteurs d'adn-pk |
DK18207382.5T DK3527563T3 (da) | 2013-03-12 | 2014-03-12 | Dna-pk-inhibitorer |
EP18207382.5A EP3527563B1 (fr) | 2013-03-12 | 2014-03-12 | Inhibiteurs d'adn-pk |
SI201431104T SI2970218T1 (sl) | 2013-03-12 | 2014-03-12 | DNA-PK inhibitorji |
PL18207382T PL3527563T3 (pl) | 2013-03-12 | 2014-03-12 | Inhibitory DNA-PK |
EP21192836.1A EP3985003B1 (fr) | 2013-03-12 | 2014-03-12 | Inhibiteurs d'adn-pk |
HRP20190373TT HRP20190373T1 (hr) | 2013-03-12 | 2019-02-26 | Inhibitori dnk-pk |
CY20211101051T CY1125436T1 (el) | 2013-03-12 | 2021-12-01 | Αναστολεις dna-pk |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361777816P | 2013-03-12 | 2013-03-12 | |
PCT/US2014/024767 WO2014159690A1 (fr) | 2013-03-12 | 2014-03-12 | Inhibiteurs d'adn-pk |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18207382.5A Division EP3527563B1 (fr) | 2013-03-12 | 2014-03-12 | Inhibiteurs d'adn-pk |
EP18207382.5A Division-Into EP3527563B1 (fr) | 2013-03-12 | 2014-03-12 | Inhibiteurs d'adn-pk |
EP21192836.1A Division EP3985003B1 (fr) | 2013-03-12 | 2014-03-12 | Inhibiteurs d'adn-pk |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2970218A1 EP2970218A1 (fr) | 2016-01-20 |
EP2970218B1 EP2970218B1 (fr) | 2018-11-28 |
EP2970218B8 true EP2970218B8 (fr) | 2019-04-10 |
Family
ID=50549437
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21192836.1A Active EP3985003B1 (fr) | 2013-03-12 | 2014-03-12 | Inhibiteurs d'adn-pk |
EP14719434.4A Active EP2970218B8 (fr) | 2013-03-12 | 2014-03-12 | Inhibiteurs d'adn-pk |
EP18207382.5A Active EP3527563B1 (fr) | 2013-03-12 | 2014-03-12 | Inhibiteurs d'adn-pk |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21192836.1A Active EP3985003B1 (fr) | 2013-03-12 | 2014-03-12 | Inhibiteurs d'adn-pk |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18207382.5A Active EP3527563B1 (fr) | 2013-03-12 | 2014-03-12 | Inhibiteurs d'adn-pk |
Country Status (26)
Country | Link |
---|---|
US (11) | US9340557B2 (fr) |
EP (3) | EP3985003B1 (fr) |
JP (2) | JP6360878B2 (fr) |
KR (1) | KR102216284B1 (fr) |
CN (2) | CN107200749B (fr) |
AU (2) | AU2014244555B2 (fr) |
BR (1) | BR112015021888B1 (fr) |
CA (1) | CA2904641C (fr) |
CY (2) | CY1121360T1 (fr) |
DK (2) | DK2970218T3 (fr) |
ES (2) | ES2900061T3 (fr) |
HK (1) | HK1220190A1 (fr) |
HR (2) | HRP20211855T1 (fr) |
HU (2) | HUE057527T2 (fr) |
IL (1) | IL241330B (fr) |
LT (2) | LT2970218T (fr) |
ME (1) | ME03336B (fr) |
MX (1) | MX365294B (fr) |
PL (2) | PL3527563T3 (fr) |
PT (2) | PT3527563T (fr) |
RS (2) | RS62649B1 (fr) |
RU (1) | RU2676259C2 (fr) |
SG (1) | SG11201507203RA (fr) |
SI (2) | SI2970218T1 (fr) |
TR (1) | TR201901886T4 (fr) |
WO (1) | WO2014159690A1 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2841428T1 (sl) | 2012-04-24 | 2018-12-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
CN107200749B (zh) | 2013-03-12 | 2019-09-03 | 沃泰克斯药物股份有限公司 | Dna-pk抑制剂 |
EP3057953B1 (fr) | 2013-10-17 | 2018-08-15 | Vertex Pharmaceuticals Incorporated | Co-cristaux de (s)-n-méthyl-8-(1-((2'-méthyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide et leurs dérivés deutérés utilisés comme inhibiteurs de protéine kinase dépendante de l'adn (dna-pk) |
EP3247701B1 (fr) | 2015-01-20 | 2021-09-22 | Boehringer Ingelheim Animal Health USA Inc. | Composés anthelmintiques, compositions et leur procédé d'utilisation |
MY190895A (en) * | 2015-01-23 | 2022-05-18 | Glaxosmithkline Ip Dev Ltd | Pyrazolo [3,4-d] pyrimidin derivative and its use for the treatment of leishmaniasis |
AU2017275657B2 (en) | 2016-06-02 | 2021-08-19 | Novartis Ag | Potassium channel modulators |
TW201815418A (zh) | 2016-09-27 | 2018-05-01 | Vertex Pharma | 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法 |
SI3571193T1 (sl) | 2017-01-23 | 2022-04-29 | Cadent Therapeutics, Inc. | Modulatorji kalijevega kanalčka |
CN107158001A (zh) * | 2017-03-29 | 2017-09-15 | 解益新 | 一种治疗哮喘的药物组合物 |
ES2940786T3 (es) * | 2018-01-17 | 2023-05-11 | Vertex Pharma | Compuestos de quinoxalinona, composiciones, métodos y kits para aumentar la eficiencia de edición del genoma |
EP3740479A1 (fr) * | 2018-01-17 | 2020-11-25 | Vertex Pharmaceuticals Incorporated | Inhibiteurs d'adn-pk |
CN111757876B (zh) * | 2018-01-17 | 2024-03-22 | 沃泰克斯药物股份有限公司 | Dna-pk抑制剂 |
MA54758A (fr) | 2019-01-18 | 2022-04-27 | Astrazeneca Ab | Inhibiteurs de pcsk9 et leurs procédés d'utilisation |
CN111909147B (zh) * | 2019-05-10 | 2021-07-20 | 山东轩竹医药科技有限公司 | Dna-pk抑制剂 |
TW202110849A (zh) * | 2019-05-27 | 2021-03-16 | 大陸商迪哲(江蘇)醫藥股份有限公司 | Dna依賴性蛋白激酶抑制劑 |
KR20220070443A (ko) | 2019-08-27 | 2022-05-31 | 버텍스 파마슈티칼스 인코포레이티드 | 반복성 dna와 연관된 장애의 치료용 조성물 및 방법 |
CA3150516A1 (fr) * | 2019-09-11 | 2021-03-18 | Provincial Health Services Authority | Composes inhibiteurs de l'adn-pk |
EP4045506A4 (fr) * | 2019-10-15 | 2023-08-30 | Aucentra Therapeutics Pty Ltd | Dérivés de 4-(imidazo[1,2-a] pyridin-3-yl)-n-(pyridin-3-yl)pyrimidin-2-amine pour le traitement de maladies et d'affections prolifératives |
BR112022008000A2 (pt) * | 2019-11-21 | 2022-07-12 | Jiangsu Hengrui Medicine Co | Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo |
WO2021136462A1 (fr) * | 2019-12-31 | 2021-07-08 | 成都百裕制药股份有限公司 | Dérivés furane et leur application en médecine |
CN113121573A (zh) * | 2019-12-31 | 2021-07-16 | 成都百裕制药股份有限公司 | 嘌呤衍生物及其在医药上的应用 |
EP4143304A2 (fr) | 2020-04-28 | 2023-03-08 | Intellia Therapeutics, Inc. | Procédés d'administration de cellules in vitro |
EP4217357A1 (fr) * | 2020-09-24 | 2023-08-02 | Auckland Uniservices Limited | Nouvelles aminopyridines et leur utilisation dans le traitement du cancer |
IL305307A (en) * | 2021-02-19 | 2023-10-01 | Kalvista Pharmaceuticals Ltd | Factor XIIA inhibitors |
EP4298222A1 (fr) | 2021-02-26 | 2024-01-03 | Vertex Pharmaceuticals Incorporated | Compositions et méthodes de traitement de la dystrophie myotonique de type 1 avec crispr/sacas9 |
WO2022182959A1 (fr) | 2021-02-26 | 2022-09-01 | Vertex Pharmaceuticals Incorporated | Compositions et méthodes pour le traitement de la dystrophie myotonique de type 1 avec crispr/slucas9 |
CA3213120A1 (fr) * | 2021-03-10 | 2022-09-15 | adMare Therapeutics Society | Derives 7-morpholino-1,6-naphtyridin-5-yle et leurs compositions pharmaceutiques utiles en tant qu'inhibiteur de l'adn-pk |
KR20240017791A (ko) | 2021-04-17 | 2024-02-08 | 인텔리아 테라퓨틱스, 인크. | Dna-의존적 단백질 키나제의 억제제 및 이의 조성물 및 용도 |
WO2023018637A1 (fr) | 2021-08-09 | 2023-02-16 | Vertex Pharmaceuticals Incorporated | Édition génique d'éléments régulateurs |
Family Cites Families (175)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571506A (en) | 1989-08-14 | 1996-11-05 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aromatic oligomeric compounds useful as mimics of bioactive macromolecules |
JPH05503517A (ja) | 1989-12-18 | 1993-06-10 | バージニア・コモンウェルス・ユニバーシティ | シグマレセプターリガンド及びその用途 |
ATE156120T1 (de) | 1991-02-07 | 1997-08-15 | Roussel Uclaf | Bizyklische stickstoffverbindungen, ihre herstellung, erhaltene zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen |
US6004979A (en) | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
EP0519211A1 (fr) | 1991-05-17 | 1992-12-23 | Hoechst Schering AgrEvo GmbH | 4-Aminopyrimidines substituées, procédé pour leur préparation et leur utilisation comme parasiticide |
DE4208254A1 (de) | 1992-03-14 | 1993-09-16 | Hoechst Ag | Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid |
WO1993022291A1 (fr) | 1992-04-24 | 1993-11-11 | E.I. Du Pont De Nemours And Company | Aminopyrimidines arthropidicides et fongicides |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
DE4437406A1 (de) | 1994-10-19 | 1996-04-25 | Hoechst Ag | Chinoxaline, Verfahren zu ihrer Herstellung und ihre Verwendung |
US5977117A (en) | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
EP0968206B8 (fr) | 1997-02-19 | 2007-01-24 | Berlex, Inc. | Derives n-heterocycliques utiles en tant qu'inhibiteurs de la no synthetase |
JPH10251255A (ja) | 1997-03-14 | 1998-09-22 | Nissan Chem Ind Ltd | アジン誘導体 |
WO1998054156A1 (fr) * | 1997-05-28 | 1998-12-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | COMPOSES QUINOLINE ET QUINOXALINE INHIBANT LE FACTEUR DE CROISSANCE DERIVE DES PLAQUETTES ET/OU LES TYROSINE-KINASES P56?lck¿ |
DE19801598C2 (de) | 1998-01-17 | 2000-05-11 | Aventis Res & Tech Gmbh & Co | Katalytische Synthese von N-alkylierten Anilinen aus Olefinen und Anilinen |
DE19836697A1 (de) | 1998-08-13 | 2000-02-17 | Hoechst Marion Roussel De Gmbh | Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
EP1147094A1 (fr) | 1999-01-15 | 2001-10-24 | Novo Nordisk A/S | Agonistes non peptidiques de glp-1 |
WO2001025220A1 (fr) | 1999-10-07 | 2001-04-12 | Amgen Inc. | Inhibiteurs de triazine kinase |
GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
US6552016B1 (en) | 1999-10-14 | 2003-04-22 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
WO2001057021A2 (fr) | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | 2-[1H]-QUINOLONE ET 2-[1H]-QUINOXALONE INHIBITEURS DU FACTEUR Xa |
DE60115394T2 (de) | 2000-02-29 | 2006-10-19 | Millennium Pharmaceuticals, Inc., Cambridge | Benzamide und ähnliche inhibitoren vom faktor xa |
AU2001245401A1 (en) | 2000-03-01 | 2001-09-12 | Sumitomo Pharmaceuticals Company, Limited | Hydrazones and analogs as cholesterol lowering agents |
DE10013318A1 (de) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
EP1351946A2 (fr) | 2000-09-01 | 2003-10-15 | Icos Corporation | Substances potentialisant un traitement anticancereux et methodes a cet effet |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP1317449B1 (fr) | 2000-09-15 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Composes de pyrazole utiles comme inhibiteurs de proteine kinase |
US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
CA2430539C (fr) | 2000-12-05 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de kinases c-jun n-terminales (jnk) et d'autres proteines kinases |
ES2265450T3 (es) | 2000-12-21 | 2007-02-16 | Vertex Pharmaceuticals Incorporated | Compuestos de pirazol utiles como inhibidores de la proteina quinasa. |
JP2004521901A (ja) | 2001-02-02 | 2004-07-22 | グラクソ グループ リミテッド | Tgf阻害剤としてのピラゾール |
MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
ES2292753T4 (es) | 2001-03-29 | 2009-02-16 | Vertex Pharmaceuticals Incorporated | Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas. |
EP1389206B1 (fr) | 2001-04-13 | 2006-09-13 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de c-jun n-terminal kinases (jnk) et d'autres proteines kinases |
EP1383771A1 (fr) | 2001-04-20 | 2004-01-28 | Vertex Pharmaceuticals Incorporated | Derives de 9-deazaguanine utilises comme inhibiteurs de la gsk-3 |
JP4316893B2 (ja) | 2001-05-16 | 2009-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Srcおよび他のプロテインキナーゼのインヒビター |
MXPA03010961A (es) | 2001-05-31 | 2004-02-27 | Vertex Pharma | Compuestos de tiazol utiles como inhibidores de proteinas cinasas. |
JP4523271B2 (ja) | 2001-06-01 | 2010-08-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチアゾール化合物 |
MXPA03011652A (es) | 2001-06-15 | 2004-05-31 | Vertex Pharma | 5-(2-aminopirimidin-4-il) benzioxazoles como inhibidores de proteinas cinasa. |
ATE337312T1 (de) | 2001-07-03 | 2006-09-15 | Vertex Pharma | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen |
GB0119865D0 (en) * | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
CA2469316A1 (fr) | 2001-12-07 | 2003-06-19 | Vertex Pharmaceuticals, Inc. | Composes a base de pyrimidine utiles en tant qu'inhibiteurs des gsk-3 |
AU2003215087B2 (en) | 2002-02-06 | 2009-07-16 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds useful as inhibitors of GSK-3 |
US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
US20030207873A1 (en) | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
EP1506189A1 (fr) | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Derives de pyrrole utilises en tant qu'inhibiteurs de erk2 et leurs utilisations |
JP4681302B2 (ja) | 2002-05-06 | 2011-05-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | チアジアゾールまたはオキサジアゾール、およびこれらの、jakプロテインキナーゼのインヒビターとしての使用 |
JP2005528443A (ja) | 2002-05-30 | 2005-09-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | Jakキナーゼおよびcdk2プロテインキナーゼのインヒビター |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
WO2004005283A1 (fr) | 2002-07-09 | 2004-01-15 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles et thiazoles presentant des activites d'inhibition des proteines kinases |
US7304071B2 (en) | 2002-08-14 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
US7419984B2 (en) | 2002-10-17 | 2008-09-02 | Cell Therapeutics, Inc. | Pyrimidines and uses thereof |
DE60330895D1 (de) | 2002-11-01 | 2010-02-25 | Vertex Pharma | Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen |
JP4688498B2 (ja) | 2002-11-04 | 2011-05-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | Jakインヒビターとしてのヘテロアリール−ピリミジン誘導体 |
WO2004058749A1 (fr) | 2002-12-18 | 2004-07-15 | Vertex Pharmaceuticals Incorporated | Derives de benzisoxazole utiles en tant qu'inhibiteurs des proteine kinases |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
CA2515132C (fr) | 2003-02-07 | 2012-01-03 | Vertex Pharmaceuticals Incorporated | Pyrroles a substitution heteroaryle servant d'inhibiteurs de proteines kinases |
AU2004221881A1 (en) | 2003-03-13 | 2004-09-30 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
AU2004223866A1 (en) | 2003-03-24 | 2004-10-07 | Luitpold Pharmaceuticals, Inc. | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors |
JP2006524688A (ja) | 2003-03-25 | 2006-11-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチアゾール |
US6875781B2 (en) | 2003-04-04 | 2005-04-05 | Cell Therapeutics, Inc. | Pyridines and uses thereof |
US7189724B2 (en) | 2003-04-15 | 2007-03-13 | Valeant Research And Development | Quinoxaline derivatives having antiviral activity |
EP1678147B1 (fr) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Derives d'aminopyrimidine a disubstitution 4,6 actifs sur le plan pharmaceutique en tant que modulateurs des proteine kinases |
AU2004313928A1 (en) | 2003-12-02 | 2005-07-28 | Vertex Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors and uses thereof |
WO2005056547A2 (fr) | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines utiles comme inhibiteurs des proteines kinases |
TW200533357A (en) | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
PT1725233E (pt) | 2004-03-15 | 2011-03-23 | Sunesis Pharmaceuticals Inc | Composição farmacêutica compreendendo sns-595 e suas utilizações |
GB0405985D0 (en) | 2004-03-17 | 2004-04-21 | Novartis Forschungsstiftung | Kinase |
KR20070012555A (ko) | 2004-05-14 | 2007-01-25 | 버텍스 파마슈티칼스 인코포레이티드 | 피롤릴피리미딘 erk 단백질 키나제 억제제의 프로드럭 |
JP4449580B2 (ja) | 2004-05-31 | 2010-04-14 | 宇部興産株式会社 | 4−アラルキルアミノピリミジン誘導体及び抗菌剤 |
CA2568451A1 (fr) | 2004-06-04 | 2005-12-22 | Arena Pharmaceuticals, Inc. | Derives d'aryle et d'heteroaryle substitues tenant lieu de modulateurs du metabolisme et prevention et traitement de troubles associes |
ES2359007T3 (es) | 2004-09-17 | 2011-05-17 | Vertex Pharmaceuticals Incorporated | Compuestos de diaminotriazol útiles como inhibidores de proteínas quinasas. |
US9611230B2 (en) | 2004-10-13 | 2017-04-04 | Ptc Therapeutics, Inc. | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
AU2005293384A1 (en) | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Quinoxalines as B Raf inhibitors |
GT200500284A (es) | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
US20060166936A1 (en) | 2004-10-29 | 2006-07-27 | Hayley Binch | Diaminotriazole compounds useful as inhibitors of protein kinases |
US7517870B2 (en) | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
CA2590250A1 (fr) | 2004-12-14 | 2006-06-22 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de la proteine kinase erk et utilisations |
EP1833820A1 (fr) | 2004-12-23 | 2007-09-19 | Vertex Pharmaceuticals Incorporated | Inhibiteurs selectifs de la proteine kinase erk et leurs utilisations |
AU2006210513C1 (en) | 2005-02-04 | 2012-10-25 | Senomyx, Inc. | Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions |
RU2007140733A (ru) | 2005-04-06 | 2009-05-20 | Айрм Ллк (Bm) | Диариламинсодержащие соединения и композиции, и их применение в качестве модуляторов ядерных рецепторов стероидного гормона |
AR054438A1 (es) | 2005-04-15 | 2007-06-27 | Kudos Pharm Ltd | Inhibidores de adn -pk |
JP2008542219A (ja) | 2005-05-25 | 2008-11-27 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | 疼痛処置法 |
WO2006138418A2 (fr) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Amelioration de la performance cognitive avec des activateurs de sirtuine |
JP2007008045A (ja) | 2005-06-30 | 2007-01-18 | Mitsui Chemicals Inc | 光記録媒体および1h−キノキサリン−2−オン誘導体 |
WO2007014250A2 (fr) | 2005-07-26 | 2007-02-01 | Vertex Pharmaceuticals Incorporated | Inhibition de kinase d'abl |
GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
JP2009514875A (ja) | 2005-11-02 | 2009-04-09 | サイトキネティクス・インコーポレーテッド | 化学物質、組成物、および方法 |
BRPI0619704A2 (pt) | 2005-11-03 | 2011-10-11 | Vertex Pharma | composto, composição, método para inibir a atividade da proteìna aurora quinase numa amostra biológica, método para tratar um distúrbio proliferativo e método para tratar cáncer |
EP1951716B1 (fr) | 2005-11-16 | 2011-05-04 | Vertex Pharmaceuticals, Inc. | Aminopyrimidines utiles en tant qu inhibiteurs de la kinase |
EP1983823A1 (fr) | 2006-01-17 | 2008-10-29 | VIB vzw | Inhibiteurs de la prolyl-hydroxylase 1 pour le traitement de la degenerescence des muscles du squelette |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
US8013153B2 (en) | 2006-03-23 | 2011-09-06 | Janssen Pharmaceutica, N.V. | Substituted pyrimidine kinase inhibitors |
US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
WO2008008852A2 (fr) | 2006-07-11 | 2008-01-17 | Emory University | Antagonistes de cxcr4 comprenant des hétéroatomes pour le traitement de troubles médicaux |
TW200811134A (en) | 2006-07-12 | 2008-03-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
AU2007271964B2 (en) | 2006-07-14 | 2012-01-19 | Novartis Ag | Pyrimidine derivatives as ALK-5 inhibitors |
US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
US8541428B2 (en) | 2006-08-22 | 2013-09-24 | Technion Research And Development Foundation Ltd. | Heterocyclic derivatives, pharmaceutical compositions and methods of use thereof |
EP1903038A1 (fr) | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | Dérivés N-(1-hetaryl-piperidine-4-yl)-(het)arylamide utilisées comme modulateurs du recepteur EP2 |
US7875603B2 (en) | 2006-09-21 | 2011-01-25 | Nova Southeastern University | Specific inhibitors for vascular endothelial growth factor receptors |
KR101101675B1 (ko) | 2006-10-02 | 2011-12-30 | 노파르티스 아게 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
DE102006050512A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte heterocyclische Verbindungen und ihre Verwendung |
JP2010509231A (ja) | 2006-11-02 | 2010-03-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼの阻害剤として有用なアミノピリジンおよびアミノピリミジン |
CN101679371A (zh) | 2006-12-04 | 2010-03-24 | 艾美罗股份公司 | 作为腺苷受体拮抗剂的取代的嘧啶 |
CA2673353A1 (fr) | 2006-12-19 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Aminopyridines utiles comme inhibiteurs de proteine kinases |
AU2007341997A1 (en) | 2006-12-28 | 2008-07-10 | Ambrx, Inc. | Phenazine and quinoxaline substituted amino acids and polypeptides |
WO2008092199A1 (fr) | 2007-01-31 | 2008-08-07 | Cytopia Research Pty Ltd | Composés à base de thiopyrimidine et ses utilisations |
WO2008106202A1 (fr) | 2007-02-27 | 2008-09-04 | Housey Gerard M | Modulateurs de théramutéine |
WO2008112651A2 (fr) | 2007-03-09 | 2008-09-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines utiles en tant qu'inhibiteurs des protéines kinases |
EP2134709A1 (fr) | 2007-03-09 | 2009-12-23 | Vertex Pharmaceuticals, Inc. | Utilisation des aminopyridines comme inhibiteurs de protéines kinases |
CA2679884A1 (fr) | 2007-03-09 | 2008-09-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines utiles en tant qu'inhibiteurs des proteines kinases |
WO2008115973A2 (fr) | 2007-03-20 | 2008-09-25 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines utiles en tant qu'inhibiteurs de kinase |
DE102007015169A1 (de) | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
NZ580343A (en) | 2007-04-13 | 2012-03-30 | Vertex Pharma | Aminopyrimidines useful as kinase inhibitors |
US7910587B2 (en) | 2007-04-26 | 2011-03-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl dipeptide hepatitis C virus inhibitors |
MX2009011811A (es) | 2007-05-02 | 2010-01-14 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasa. |
WO2008137621A1 (fr) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines servant d'inhibiteurs de kinases |
MX2009011810A (es) | 2007-05-02 | 2010-01-14 | Vertex Pharma | Tiazoles y pirazoles utiles como inhibidores de cinasa. |
US20100234386A1 (en) | 2007-05-10 | 2010-09-16 | Chaudhari Amita | Quinoxaline derivatives as pi3 kinase inhibitors |
WO2008144253A1 (fr) | 2007-05-14 | 2008-11-27 | Irm Llc | Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci |
JP2010528021A (ja) | 2007-05-24 | 2010-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼのインヒビターとして有用なチアゾールおよびピラゾール |
AU2008257559B2 (en) | 2007-05-25 | 2013-10-10 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (MGLU2 receptor) |
US8685962B2 (en) | 2007-07-02 | 2014-04-01 | Technion Research & Development Foundation Limited | Compositions, articles and methods comprising TSPO ligands for preventing or reducing tobacco-associated damage |
WO2009008991A2 (fr) | 2007-07-06 | 2009-01-15 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Modulation de la régulation d'énergie et de la fonction cérébrale par adn-pkcs |
UY31232A1 (es) | 2007-07-19 | 2009-03-02 | Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones | |
BRPI0813863B1 (pt) | 2007-08-01 | 2016-09-27 | Ihara Chemical Ind Co | derivado de oxopirazina ou um sal agroquimicamente aceitável do mesmo, herbicida, e, método para usar um herbicida |
EP2190466A4 (fr) | 2007-08-10 | 2011-12-21 | Burnham Inst Medical Research | Activateurs de la phosphatase alcaline non spécifique des tissus (tnap) et leurs utilisations |
DE102007044032A1 (de) | 2007-09-14 | 2009-03-19 | Bayer Healthcare Ag | Substituierte heterocyclische Verbindungen und ihre Verwendung |
ATE510827T1 (de) | 2007-10-12 | 2011-06-15 | Ingenium Pharmaceuticals Gmbh | Inhibitoren von proteinkinasen |
WO2009061761A2 (fr) | 2007-11-06 | 2009-05-14 | E. I. Du Pont De Nemours And Company | Amines fongicides |
WO2009091388A2 (fr) | 2007-12-21 | 2009-07-23 | Progenics Pharmaceuticals, Inc. | Triazines et composés associés présentant une activité antivirale, compositions et procédés associés |
WO2009105220A1 (fr) | 2008-02-19 | 2009-08-27 | Janssen Pharmaceutica N.V. | Aryl-hydroxyéthylamino-pyrimidines et triazines en tant que modulateurs d'amide d'acide gras hydrolase |
WO2009107391A1 (fr) | 2008-02-27 | 2009-09-03 | 武田薬品工業株式会社 | Composé contenant un cycle aromatique à 6 chaînons |
MX2010009576A (es) | 2008-03-05 | 2010-09-24 | Merck Patent Gmbh | Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes. |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
US20110065739A1 (en) | 2008-06-02 | 2011-03-17 | Makoto Ishikawa | Novel isoxazole drivative |
AU2009259754B2 (en) | 2008-06-16 | 2014-10-02 | Merck Patent Gmbh | Quinoxalinedione derivatives |
EP2138488A1 (fr) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Dérivés de 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-ones comme inhibiteurs de GSK3-beta utiles pour le traitement de maladies neurodégénératives |
ES2402087T3 (es) | 2008-07-23 | 2013-04-26 | Vertex Pharmaceuticals Incorporated | Inhibidores de la pirazolopiridina quinasa |
WO2010048149A2 (fr) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie |
UY32251A (es) | 2008-11-20 | 2010-05-31 | Glaxosmithkline Llc | Compuestos quimicos |
WO2010065899A2 (fr) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Complexes de technétium- et rhénium-bis (hétéroaryles) et leurs procédés d'utilisation |
RS56995B1 (sr) | 2008-12-19 | 2018-05-31 | Vertex Pharma | Derivati pirazina korisni kao inhibitori atr kinaze |
WO2010093808A1 (fr) | 2009-02-11 | 2010-08-19 | Reaction Biology Corp. | Inhibiteurs de kinase sélectifs |
JP2010111702A (ja) | 2009-02-16 | 2010-05-20 | Tetsuya Nishio | 複素環化合物、その製造法および用途 |
WO2011022348A1 (fr) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Modulateurs d'éthylène diamine d'une amide hydrolase d'acide gras |
AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
EP2947073B1 (fr) | 2009-10-22 | 2019-04-03 | Fibrotech Therapeutics Pty Ltd | Analogues cycliques fusionnés d'agents antifibrotiques |
ES2360333B1 (es) | 2009-10-29 | 2012-05-04 | Consejo Superior De Investigaciones Cientificas (Csic) (70%) | Derivados de bis (aralquil) amino y sistemas (hetero) aromaticos de seis miembros y su uso en el tratamiento de patologias neurodegenerativas, incluida la enfermedad de alzheimer |
EP2495238A4 (fr) | 2009-10-30 | 2013-04-24 | Mochida Pharm Co Ltd | Nouveau dérivé de 3-hydroxy-5-arylisoxazole |
WO2011078371A1 (fr) | 2009-12-25 | 2011-06-30 | 持田製薬株式会社 | Nouveau dérivé 3-hydroxy-5-arylisothiazole |
UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
JP2013522249A (ja) | 2010-03-16 | 2013-06-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | モルホリニルキナゾリン |
TWI516264B (zh) | 2010-05-06 | 2016-01-11 | 臺北醫學大學 | 芳香醯喹啉化合物 |
JP2011246389A (ja) * | 2010-05-26 | 2011-12-08 | Oncotherapy Science Ltd | Ttk阻害作用を有する縮環ピラゾール誘導体 |
DE102010025786A1 (de) | 2010-07-01 | 2012-01-05 | Merck Patent Gmbh | Pyrazolochinoline |
DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
WO2012129562A2 (fr) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Composés et procédés pour l'induction de la chondrogenèse |
GB201114051D0 (en) | 2011-08-15 | 2011-09-28 | Domainex Ltd | Compounds and their uses |
ES2725790T3 (es) | 2011-08-26 | 2019-09-27 | Neupharma Inc | Algunas entidades químicas, composiciones, y métodos |
CN108794411B (zh) | 2011-09-14 | 2022-06-07 | 润新生物公司 | 某些化学实体、组合物及方法 |
US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
US9249111B2 (en) | 2011-09-30 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-RAF kinase inhibitors |
DE102011118830A1 (de) | 2011-11-18 | 2013-05-23 | Merck Patent Gmbh | Morpholinylbenzotriazine |
GB201120993D0 (en) | 2011-12-06 | 2012-01-18 | Imp Innovations Ltd | Novel compounds and their use in therapy |
WO2013112950A2 (fr) | 2012-01-25 | 2013-08-01 | Neupharma, Inc. | Entités chimiques particulières, compositions et procédés |
SI2841428T1 (sl) | 2012-04-24 | 2018-12-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
US9725421B2 (en) | 2012-11-12 | 2017-08-08 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
CN107200749B (zh) | 2013-03-12 | 2019-09-03 | 沃泰克斯药物股份有限公司 | Dna-pk抑制剂 |
EP3057953B1 (fr) | 2013-10-17 | 2018-08-15 | Vertex Pharmaceuticals Incorporated | Co-cristaux de (s)-n-méthyl-8-(1-((2'-méthyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide et leurs dérivés deutérés utilisés comme inhibiteurs de protéine kinase dépendante de l'adn (dna-pk) |
-
2014
- 2014-03-12 CN CN201710472183.0A patent/CN107200749B/zh active Active
- 2014-03-12 SI SI201431104T patent/SI2970218T1/sl unknown
- 2014-03-12 PL PL18207382T patent/PL3527563T3/pl unknown
- 2014-03-12 BR BR112015021888-1A patent/BR112015021888B1/pt active IP Right Grant
- 2014-03-12 SG SG11201507203RA patent/SG11201507203RA/en unknown
- 2014-03-12 US US14/205,657 patent/US9340557B2/en active Active
- 2014-03-12 KR KR1020157028350A patent/KR102216284B1/ko active IP Right Grant
- 2014-03-12 LT LTEP14719434.4T patent/LT2970218T/lt unknown
- 2014-03-12 EP EP21192836.1A patent/EP3985003B1/fr active Active
- 2014-03-12 RS RS20211467A patent/RS62649B1/sr unknown
- 2014-03-12 ES ES18207382T patent/ES2900061T3/es active Active
- 2014-03-12 ES ES14719434T patent/ES2711839T3/es active Active
- 2014-03-12 TR TR2019/01886T patent/TR201901886T4/tr unknown
- 2014-03-12 PT PT182073825T patent/PT3527563T/pt unknown
- 2014-03-12 HU HUE18207382A patent/HUE057527T2/hu unknown
- 2014-03-12 CN CN201480025199.1A patent/CN105246883B/zh active Active
- 2014-03-12 WO PCT/US2014/024767 patent/WO2014159690A1/fr active Application Filing
- 2014-03-12 AU AU2014244555A patent/AU2014244555B2/en active Active
- 2014-03-12 LT LTEP18207382.5T patent/LT3527563T/lt unknown
- 2014-03-12 DK DK14719434.4T patent/DK2970218T3/en active
- 2014-03-12 EP EP14719434.4A patent/EP2970218B8/fr active Active
- 2014-03-12 CA CA2904641A patent/CA2904641C/fr active Active
- 2014-03-12 RS RS20190243A patent/RS58374B1/sr unknown
- 2014-03-12 DK DK18207382.5T patent/DK3527563T3/da active
- 2014-03-12 SI SI201431922T patent/SI3527563T1/sl unknown
- 2014-03-12 US US14/205,508 patent/US9359380B2/en active Active
- 2014-03-12 ME MEP-2019-55A patent/ME03336B/fr unknown
- 2014-03-12 HU HUE14719434A patent/HUE041544T2/hu unknown
- 2014-03-12 EP EP18207382.5A patent/EP3527563B1/fr active Active
- 2014-03-12 PT PT14719434T patent/PT2970218T/pt unknown
- 2014-03-12 MX MX2015012502A patent/MX365294B/es active IP Right Grant
- 2014-03-12 JP JP2016501636A patent/JP6360878B2/ja active Active
- 2014-03-12 HR HRP20211855TT patent/HRP20211855T1/hr unknown
- 2014-03-12 RU RU2015143211A patent/RU2676259C2/ru active
- 2014-03-12 PL PL14719434T patent/PL2970218T3/pl unknown
-
2015
- 2015-09-08 IL IL241330A patent/IL241330B/en active IP Right Grant
-
2016
- 2016-04-20 US US15/133,378 patent/US9987284B2/en active Active
- 2016-05-06 US US15/148,229 patent/US20160354381A1/en not_active Abandoned
- 2016-07-13 HK HK16108234.1A patent/HK1220190A1/zh unknown
-
2017
- 2017-07-25 US US15/659,306 patent/US10258627B2/en active Active
-
2018
- 2018-04-27 US US15/965,489 patent/US20180311254A1/en not_active Abandoned
- 2018-05-14 JP JP2018092924A patent/JP2018135389A/ja not_active Withdrawn
- 2018-09-27 AU AU2018236800A patent/AU2018236800B2/en active Active
-
2019
- 2019-02-20 CY CY20191100217T patent/CY1121360T1/el unknown
- 2019-02-21 US US16/282,083 patent/US10786512B2/en active Active
- 2019-02-26 HR HRP20190373TT patent/HRP20190373T1/hr unknown
- 2019-04-01 US US16/372,080 patent/US10973830B2/en active Active
-
2020
- 2020-09-17 US US17/023,597 patent/US11813267B2/en active Active
-
2021
- 2021-02-09 US US17/171,061 patent/US20210236505A1/en not_active Abandoned
- 2021-12-01 CY CY20211101051T patent/CY1125436T1/el unknown
-
2023
- 2023-02-27 US US18/175,515 patent/US20230277547A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190373T1 (hr) | Inhibitori dnk-pk | |
HUE037516T2 (hu) | DNS-PK inhibitorok | |
EP2968276A4 (fr) | Inhibiteurs hybrides de la nécroptose | |
EP3082809A4 (fr) | Inhibiteurs de btk | |
HK1211578A1 (en) | Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1 | |
HK1216531A1 (zh) | 新的抑制劑 | |
EP3082811A4 (fr) | Inhibiteurs de btk | |
EP3003372A4 (fr) | Inhibiteurs du facteur h du complément | |
EP2994124A4 (fr) | Inhibiteurs d'enzymes métallo-ss-lactamase | |
IL246230A0 (en) | Amines thf quinazoline as pde1 inhibitors | |
EP3071572A4 (fr) | Inhibiteurs de protéines kinases | |
EP2994143A4 (fr) | Inhibiteurs de stat6 | |
HK1213885A1 (zh) | 作為 抑制劑的咪唑並-三嗪衍生物 | |
EP3074401A4 (fr) | Inhibiteurs de protéines kinases | |
EP2968324A4 (fr) | Dérivés de pyridizinone substitués en tant qu'inhibiteurs de pde10 | |
EP3082810A4 (fr) | Inhibiteurs d'erk | |
EP3071573A4 (fr) | Inhibiteurs de protéines kinases | |
EP2945930A4 (fr) | Nouveaux inhibiteurs de ddp-iv | |
AU2013901594A0 (en) | Ai |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20151002 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20161213 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1220190 Country of ref document: HK |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20170531 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20180606 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1070068 Country of ref document: AT Kind code of ref document: T Effective date: 20181215 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014036896 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: RO Ref legal event code: EPE |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20190373 Country of ref document: HR |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: VERTEX PHARMACEUTICALS INC. |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 2970218 Country of ref document: PT Date of ref document: 20190301 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20190225 |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: VERTEX PHARMACEUTICALS INCORPORATED |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PK Free format text: BERICHTIGUNG B8 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20190318 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: FG4A Ref document number: E016962 Country of ref document: EE Effective date: 20190222 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20190373 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2711839 Country of ref document: ES Kind code of ref document: T3 Effective date: 20190507 |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20181128 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E041544 Country of ref document: HU |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20190400648 Country of ref document: GR Effective date: 20190509 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014036896 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20190373 Country of ref document: HR Payment date: 20190402 Year of fee payment: 6 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20190829 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20190373 Country of ref document: HR Payment date: 20200226 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20190373 Country of ref document: HR Payment date: 20210223 Year of fee payment: 8 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20190373 Country of ref document: HR Payment date: 20220221 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MK Payment date: 20220221 Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20190373 Country of ref document: HR Payment date: 20230221 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SM Payment date: 20230223 Year of fee payment: 10 Ref country code: RO Payment date: 20230227 Year of fee payment: 10 Ref country code: NO Payment date: 20230329 Year of fee payment: 10 Ref country code: MC Payment date: 20230222 Year of fee payment: 10 Ref country code: LU Payment date: 20230327 Year of fee payment: 10 Ref country code: LT Payment date: 20230220 Year of fee payment: 10 Ref country code: IE Payment date: 20230327 Year of fee payment: 10 Ref country code: FR Payment date: 20230327 Year of fee payment: 10 Ref country code: FI Payment date: 20230327 Year of fee payment: 10 Ref country code: DK Payment date: 20230329 Year of fee payment: 10 Ref country code: CZ Payment date: 20230301 Year of fee payment: 10 Ref country code: BG Payment date: 20230322 Year of fee payment: 10 Ref country code: AT Payment date: 20230221 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20230224 Year of fee payment: 10 Ref country code: SK Payment date: 20230220 Year of fee payment: 10 Ref country code: SI Payment date: 20230221 Year of fee payment: 10 Ref country code: SE Payment date: 20230315 Year of fee payment: 10 Ref country code: RS Payment date: 20230221 Year of fee payment: 10 Ref country code: PT Payment date: 20230222 Year of fee payment: 10 Ref country code: PL Payment date: 20230221 Year of fee payment: 10 Ref country code: LV Payment date: 20230222 Year of fee payment: 10 Ref country code: IT Payment date: 20230321 Year of fee payment: 10 Ref country code: IS Payment date: 20230220 Year of fee payment: 10 Ref country code: HU Payment date: 20230303 Year of fee payment: 10 Ref country code: HR Payment date: 20230221 Year of fee payment: 10 Ref country code: GR Payment date: 20230331 Year of fee payment: 10 Ref country code: GB Payment date: 20230327 Year of fee payment: 10 Ref country code: EE Payment date: 20230220 Year of fee payment: 10 Ref country code: DE Payment date: 20230329 Year of fee payment: 10 Ref country code: CY Payment date: 20230222 Year of fee payment: 10 Ref country code: BE Payment date: 20230327 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230326 Year of fee payment: 10 Ref country code: MT Payment date: 20230220 Year of fee payment: 10 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230528 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20230403 Year of fee payment: 10 Ref country code: CH Payment date: 20230402 Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 1070068 Country of ref document: AT Kind code of ref document: T Effective date: 20181128 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AL Payment date: 20230307 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MK Payment date: 20230221 Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20190373 Country of ref document: HR Payment date: 20240221 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20240327 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IS Payment date: 20240228 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LT Payment date: 20240220 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20240327 Year of fee payment: 11 Ref country code: IE Payment date: 20240327 Year of fee payment: 11 Ref country code: NL Payment date: 20240326 Year of fee payment: 11 |